Lyrica

Country: New Zealand

Language: English

Source: Medsafe (Medicines Safety Authority)

Active ingredient:

Pregabalin 150mg

Available from:

Upjohn New Zealand ULC

Dosage:

150 mg

Pharmaceutical form:

Capsule

Composition:

Active: Pregabalin 150mg Excipient: Colloidal silicon dioxide   Gelatin   Lactose monohydrate Maize starch Purified talc Purified water   Sodium laurilsulfate   TekPrint black SW-9008 TekPrint black SW-9009 Titanium dioxide  

Prescription type:

Prescription

Therapeutic indications:

Lyrica (pregabalin) is indicated for the treatment of neuropathic pain in adults. Lyrica (pregabalin) is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

Product summary:

Package - Contents - Shelf Life: Blister pack, PVC/Al - 56 capsules - 36 months from date of manufacture stored at or below 25°C

Authorization date:

2020-11-03

Patient Information leaflet

LYRICA
1
LYRICA
_(LEER-i-kah) _
CONSUMER MEDICINE INFORMATION
WHAT IS IN THIS LEAFLET
This leaflet answers some common
questions about Lyrica.
It does not contain all the available
information. It does not take the
place of talking to your doctor or
pharmacist.
All medicines have risks and
benefits. Your doctor has weighed
the risks of you taking Lyrica against
the benefits it is expected to have for
you.
IF YOU HAVE ANY CONCERNS ABOUT
TAKING THIS MEDICINE, ASK YOUR
DOCTOR OR PHARMACIST.
KEEP THIS LEAFLET WITH THE MEDICINE.
You may need to read it again.
WHAT LYRICA IS USED
FOR
Lyrica is used to treat neuropathic
pain, which is pain caused by an
abnormality of, or damage to, the
nerves.
Lyrica is also used to control
epilepsy. Epilepsy is a condition
where you have repeated seizures
(fits). There are many different types
of seizures, ranging from mild to
severe.
Lyrica belongs to a group of
medicines called anticonvulsants.
These medicines are thought to work
by controlling brain chemicals which
send signals to nerves so that seizures
do not happen.
Lyrica also has pain relieving effects.
Lyrica may be used alone, or in
combination with other medicines, to
treat your condition.
Your doctor may prescribe Lyrica in
addition to your current therapy
when your current treatment is no
longer working as well as before.
ASK YOUR DOCTOR IF YOU HAVE ANY
QUESTIONS ABOUT WHY LYRICA HAS
BEEN PRESCRIBED FOR YOU.
Your doctor may have prescribed it
for another reason.
This medicine is available only with
a doctor's prescription.
_USE IN CHILDREN _
There is not enough information to
recommend the use of this medicine
in children under the age of 18 years.
BEFORE YOU TAKE LYRICA
_WHEN YOU MUST NOT TAKE IT _
DO NOT TAKE LYRICA IF YOU HAVE AN
ALLERGY TO:
•
pregabalin, the active ingredient
in Lyrica, or
•
any of the ingredients listed at the
end of this leaflet.
Some of the symptoms of an allergic
reaction may include:
•
shortness of breath, wheezing or
difficulty breathing
•
swelling of the face, lips, tongue
or other parts

Summary of Product characteristics

Version: ujdlyric11120
Supersedes: pfdpregc10120
Page 1 of 21
NEW ZEALAND DATA SHEET
1.
PRODUCT NAME
LYRICA 25 mg capsules (Australian Stock)
LYRICA 75 mg capsules (Australian Stock)
LYRICA 150 mg capsules (Australian Stock)
LYRICA 300 mg capsules (Australian Stock)
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
LYRICA
contains
the
active
ingredient
pregabalin.
Pregabalin
is
an
analogue
of
the
neurotransmitter gamma-aminobutyric acid (GABA). It has analgesic and
anticonvulsant
activity. Each LYRICA capsule contains 25 mg, 75 mg, 150 mg, or 300 mg
pregabalin.
EXCIPIENT(S) WITH KNOWN EFFECT:
•
Lactose monohydrate
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
LYRICA 25 mg capsules: white hard gelatin capsule, marked ‘Pfizer’
on the cap and ‘PGN 25’
on the body with black ink.
LYRICA 75 mg capsules: white and orange hard gelatin capsule, marked
‘Pfizer’ on the cap
and ‘PGN 75’ on the body with black ink.
LYRICA 150 mg capsules: white hard gelatin capsule, marked
‘Pfizer’ on the cap and
‘PGN 150’ on the body with black ink.
LYRICA 300 mg capsules: white and orange hard gelatin capsule, marked
‘Pfizer’ on the cap
and ‘PGN 300’ on the body with black ink.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
LYRICA (pregabalin) is indicated for the treatment of neuropathic pain
in adults.
LYRICA (pregabalin) is indicated as adjunctive therapy in adults with
partial seizures with or
without secondary generalisation.
Version: ujdlyric11120
Supersedes: pfdpregc10120
Page 2 of 21
4.2
DOSE AND METHOD OF ADMINISTRATION
DOSE
The dose range is 150 to 600 mg per day given in two divided doses.
LYRICA may be taken with or without food.
_NEUROPATHIC PAIN _
LYRICA treatment can be started at a dose of 150 mg per day, given as
two divided doses.
Based on individual patient response and tolerability, the dosage may
be increased to 300 mg
per day, given as two divided doses, after an interval of 3 to 7 days,
and if needed, to a
maximum dose of 600 mg per day after an additional 7